跳转至内容
Merck

T-905

Supelco

Thioridazine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H26N2S2
CAS号:
分子量:
370.57
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
价格与库存信息目前不能提供

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

CSc1ccc2Sc3ccccc3N(CCC4CCCCN4C)c2c1

InChI

1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3

InChI key

KLBQZWRITKRQQV-UHFFFAOYSA-N

一般描述

An analytical reference standard applicable for use as starting material in calibrators or controls for thioridazine testing methods by LC-MS/MS or GC-MS. Thioridazine is a treatment for schizophrenia sold under trade names Mellaril, Novoridazine, and Thioril.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Eduardo Abbate et al.
The Journal of antimicrobial chemotherapy, 67(2), 473-477 (2011-12-03)
Current drug choices to treat extensively drug-resistant (XDR) tuberculosis (TB) are scarce; therefore, information on the safety, tolerability and efficacy of alternative regimens is of utmost importance. The aim of this study was to describe the management, drug adverse effects
Maija Purhonen et al.
Pharmacoepidemiology and drug safety, 21(11), 1227-1231 (2012-09-04)
Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated. Nationwide registers in Finland were utilized to study thioridazine use
Gabriella Spengler et al.
International journal of antimicrobial agents, 39(1), 16-21 (2011-10-11)
Thioridazine (TZ)-induced accumulation of the universal efflux pump substrate ethidium bromide and its subsequent efflux by Salmonella strains with various degrees of overexpressed efflux pumps takes place automatically at pH 7.4, is independent of a metabolic source, is not affected
Diana Machado et al.
PloS one, 7(4), e34538-e34538 (2012-04-12)
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy. Here, we investigated the mechanism by which resistance towards isoniazid develops and how overexpression of efflux pumps
Shen-Chieh Chang et al.
Therapeutic drug monitoring, 34(3), 345-348 (2012-05-10)
In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持